August 27, 2018
Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed.
October 28, 2019
UC San Diego Health opens a new clinic in Eastlake that offers express care and imaging capabilities with primary care opening late 2019.
February 26, 2015
…highest recognition offered by NPF to a Parkinson’s specialty clinic. It represents the consensus of leaders in the field that the UC San Diego program is among the world’s leading centers for Parkinson’s research, outreach and care.
February 4, 2016
Some of the most prominent scientists conducting very “timely” research are coming to campus.
October 27, 2011
UC San Diego Health System has been recognized by the Integrated Healthcare Association (IHA) as a top performing hospital in California. Out of over 200 physician organizations, UC San Diego Health System was recognized as a “Top Overall Physician Performing Organization” with honorable mentions in “Diabetes Care” and “IT Enabled…
October 25, 2021
Philanthropists Richard and Carol Dean Hertzberg have committed $2.1 million to develop and maintain the Dean-Hertzberg Breast Cancer Database System Initiative at UC San Diego Health Moores Cancer Center to support the work of Anne Wallace, MD and her collaborators at Moores Cancer Center.
May 11, 2017
…liver, known as fibrosis, is a major determinant of clinical outcomes.
January 4, 2022
Marking its 30th anniversary and her enduring interest and support, philanthropist Darlene Shiley has given a $10 million gift for the clinical space expansion of the Shiley Eye Institute at UC San Diego Health.
April 25, 2023
New UC San Diego Health transperineal prostate biopsy procedure now offered in clinic setting.
June 1, 2018
…a first-in-human phase I clinical trial, researchers at University of California San Diego School of Medicine have found that treatment with cirmtuzumab, an experimental monoclonal antibody-based drug, measurably inhibited the “stemness” of chronic lymphocytic leukemia cancer (CLL) cells — their ability to self-renew and resist terminal differentiation and senescence.
